Access

You are not currently logged in.

Access your personal account or get JSTOR access through your library or other institution:

login

Log in to your personal account or through your institution.

Use of International Classification of Diseases, Ninth Revision, Clinical Modification Codes and Medication Use Data to Identify Nosocomial Clostridium difficile Infection

Mia Schmiedeskamp , PharmD, PhD, Spencer Harpe , PharmD, PhD, MPH, Ronald Polk , PharmD, Michael Oinonen , PharmD, MPH and Amy Pakyz , PharmD, MS
Infection Control and Hospital Epidemiology
Vol. 30, No. 11 (November 2009), pp. 1070-1076
DOI: 10.1086/606164
Stable URL: http://www.jstor.org/stable/10.1086/606164
Page Count: 7
  • Subscribe ($19.50)
  • Cite this Item
Item Type
Article
References
Use of International Classification of Diseases, Ninth Revision, Clinical Modification Codes and Medication Use Data to Identify Nosocomial Clostridium difficile Infection
Preview not available

Abstract

Objective.  The International Classification of Diseases, Ninth Revision, Clinical Modification (ICD‐9‐CM) code for Clostridium difficile infection (CDI) is used for surveillance of CDI. However, the ICD‐9‐CM code alone cannot separate nosocomial cases from cases acquired outside the institution. The purpose of this study was to determine whether combining the ICD‐9‐CM code with medication treatment data for CDI in hospitalized patients could enable us to distinguish between patients with nosocomial CDI and patients who were admitted with CDI. The primary objective was to compare the sensitivity, specificity, and predictive value of using the combination of ICD‐9‐CM code for CDI and CDI treatment records to identify cases of nosocomial CDI with the sensitivity, specificity, and predictive value of using the ICD‐9‐CM code alone. Design.  Validation sample cross‐sectional study. Setting.  Academic health center. Methods.  Administrative claims data from July 1, 2004, to June 30, 2005, were queried to identify adults discharged with an ICD‐9‐CM code for CDI and to find documentation of CDI therapy with oral vancomycin or metronidazole. Laboratory and medical records were queried to identify symptomatic CDI toxin–positive adult patients with nosocomial CDI and were compared with records of patients whose cases were predicted to be nosocomial by means of ICD‐9‐CM code and CDI therapy data. Results.  Of 23,920 adult patients discharged from the hospital, 62 had nosocomial CDI according to symptoms and toxin assay. The sensitivity of the ICD‐9‐CM code alone for identifying nosocomial CDI was 96.8%, the specificity was 99.6%, the positive predictive value was 40.8%, and the negative predictive value was 100%. When CDI drug therapy was included with the ICD‐9‐CM code, the sensitivity ranged from 58.1% to 85.5%, specificity was virtually unchanged, and the range in positive predictive value was 37.9%–80.0%. Conclusion.  Combining the ICD‐9‐CM code for CDI with drug therapy information increased the positive predictive value for nosocomial CDI but decreased the sensitivity.

Page Thumbnails